Tarek Daoud, MD
Nephrology · Waterloo, IANPI 1780638171
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $206 of the $267 with a category attached, or 77.1%. 6 manufacturers reported payments, led by Boston Scientific at 52.8% of the total. 2025 is the largest year on record at $171, 2.8 times the $61 reported in 2019.
Across 6 payments — averaging $44.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$141
- Otsuka America Pharmaceutical, Inc.$61
- Takeda Pharmaceuticals U.S.A., Inc.$18
- Nxstage Medical, Inc.$18
- Azurity Pharmaceuticals, Inc.$17
- Travere Therapeutics, Inc.$11
What the payments were for
- Food & beverage$20677%
- Education$6123%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 1 | $141 |
| Otsuka America Pharmaceutical, Inc. | 1 | $61 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Nxstage Medical, Inc. | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| Travere Therapeutics, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$267 in reported general payments places this provider in the 55th percentile of 73 nephrology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 547 | $492,174 |
| OzempicSemaglutide | 158 | $172,041 |
| FarxigaDapagliflozin Propanediol | 136 | $117,478 |
| KerendiaFinerenone | 131 | $112,864 |
| JanuviaSitagliptin Phosphate | 107 | $93,497 |
| MounjaroTirzepatide | 85 | $90,800 |
| EliquisApixaban | 72 | $53,652 |
| TrulicityDulaglutide | 48 | $52,416 |
| Repatha SyringeEvolocumab | 71 | $49,778 |
| InvokanaCanagliflozin | 21 | $33,236 |
| TradjentaLinagliptin | 48 | $31,913 |
| RybelsusSemaglutide | 20 | $28,208 |
| MyrbetriqMirabegron | 25 | $18,239 |
| LokelmaSodium Zirconium Cyclosilicate | 26 | $12,188 |
| Sevelamer Carbonate | 135 | $9,915 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Waterloo
- Vinay KantamneniWaterloo$192
- Cristina PasarinWaterloo$123
- Craig ShadurDes Moines$314K
- Andrew BlandDubuque$76K
- Lawrence HunsickerIowa City$70K
- Ashar LuqmanSioux City$56K
- Jeremy PepinCouncil Bluffs$42K
- Prem ChandranDes Moines$19K
- Lama NoureddineIowa City$7K
- Benjamin GriffinIowa City$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.